Unregistered
12-12-2005, 02:25 PM
This may be of interest
RB.
http://www.medpagetoday.com/HematologyOncology/BreastCancer/tb/2311
ABSTRACT
SAN ANTONIO, Dec 12 - A shorter standard adjuvant chemotherapy regimen, augmented by weekly doses of Taxol (paclitaxel), led to a 37% reduction in the relative risk of recurrence of node-positive breast cancer, a Spanish study concluded.
The first interim analysis of the Spanish Group for Breast Cancer Research 9906 trial also show an improvement in overall survival for women in the Taxol arm, Miguel Martin, M.D., Ph.D., of Hospital Universitario San Carlos in Madrid reported at the San Antonio Breast Cancer Symposium here.
Importantly, he said, the effect was seen in all subgroups, including both hormone-receptor-positive and hormone-receptor -negative women.
RB.
http://www.medpagetoday.com/HematologyOncology/BreastCancer/tb/2311
ABSTRACT
SAN ANTONIO, Dec 12 - A shorter standard adjuvant chemotherapy regimen, augmented by weekly doses of Taxol (paclitaxel), led to a 37% reduction in the relative risk of recurrence of node-positive breast cancer, a Spanish study concluded.
The first interim analysis of the Spanish Group for Breast Cancer Research 9906 trial also show an improvement in overall survival for women in the Taxol arm, Miguel Martin, M.D., Ph.D., of Hospital Universitario San Carlos in Madrid reported at the San Antonio Breast Cancer Symposium here.
Importantly, he said, the effect was seen in all subgroups, including both hormone-receptor-positive and hormone-receptor -negative women.